Cosomil is a deep-tech startup for cancer screening with its proprietary ‘Single-molecule Enzyme Activity-based Liquid Biopsy’ technology that was developed by UTokyo & RIKEN. They are committed to delivering innovative solutions for early cancer detection for curative treatments such as the most lethal one, Pancreatic Cancer.

Plusman uses actuarial expertise to create advanced mathematical models and AI for medicine. Our solutions include diagnostic imaging AI, treatment planning support, medical generative AI, LLM, and Digital CDx, which predicts genetic mutations and suggests treatments based on medical data.

Rege Nephro Co., Ltd., a Kyoto University spin-off biotech startup, utilizes iPSC technology. Our lead products include RN-014, a small-molecule for autosomal dominant polycystic kidney disease (ADPKD), and RN-032, an allogeneic cell therapy for chronic kidney disease using iPSC-derived nephron progenitor cells.

SyntheticGestalt is a molecule-focused AI development company: our core technology is a foundation AI model trained on 1 billion compounds, which can be used to develop various high-performance AI models for small molecules with ease. We have already raised $14 million from Japanese and UK investors and have collaborations with major companies.

Abrax Japan, Inc. is a biotech company that harnesses the potential of an immune modulating protein called thymic stromal lymphopoietin (TSLP) for the treatment of multiple disorders including eczema, dry eye disease, obesity, obesity-related metabolic complications.

Citadel AI is a global leader in trustworthy AI technology and develops tools to evaluate, explain, and debug AI systems. Our products have been adopted by BSI (British Standards Institution). In addition, Citadel AI is trusted by public organizations such as the AI Safety Institute in the US.

The company uses "CUBIC," a three-dimensional analysis technology developed over years of research, to comprehensively analyze the distribution of drugs in organs and their cellular reactions across all organs and the entire body. They provide contract research services to pharmaceutical companies and also supply reagent kits for R&D scientists.

A start-up company from Kitasato University. Developing innovative hemodialysis device dedicated for home use, requiring only consumables (no water supply nor drainage required) to improve Quality of Life of patients with end-stage renal disease and their family. Product launch in Japan is planned in 2029.

Rebirthel provides a novel treatment method "Allogeneic off-the-shelf universal T cell therapy" for advanced and recurrent cancers that are not curative to current conventional therapies. Fundamental technologies that make this therapy realizable are patented globally. With the recently developed technology to avoid immune rejection, we provide the super universal therapy with benefits to patients.

Smart Tissues is developing the first antimicrobial and versatile bioink for bioprinting human tissues and organs. Smart Tissues' unique strength is the antimicrobial properties of their bioink and being the first bioink manufacturer in Japan.

Spine Chronicle Japan Co., Ltd.'s vision is "to create the best spinal implants for elderly patients." We wish to improve the surgical results for elderly patients with weak bones. We are developing safe and reliable surgical treatment for patients with spinal fractures and lumber spinal stenosis.